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Abstract
Background: Human cytomegalovirus infections are still significant causes of morbidity and mortality in transplant
recipients. The use of antiviral agents is limited by toxicity and evolving resistance in immunocompromised patients
with ongoing viral replication during therapy. Here, we present the first documented case of genotypic resistance
against maribavir in a bone marrow transplant (BMT) recipient.
Case presentation: The female 13-year-old patient was suffering from a refractory cytopenia. Ganciclovir, foscarnet,
cidofovir, leflunomide and maribavir, an inhibitor of the cytomegalovirus UL97 protein, were administered to treat a
therapy-resistant cytomegalovirus infection. Viral mutations conferring resistance against nucleotide and
pyrophosphate analogs as well as maribavir (MBV) have evolved sequentially. Particularly, impressive was the fast
emergence of multiple mutations T409M, H411Y and H411N conferring maribavir resistance after less than 6 weeks.
Conclusion: We describe the fast emergence of cytomegalovirus variants with different maribavir resistance
associated mutations in a bone marrow transplant recipient treated with MBV 400 mg p.o. twice per day. The
results suggest that a high virus load permitted a selection of several but distinct therapy-resistant HCMV mutants.
Since a phase II study with MBV is intended for the treatment of resistant or refractory HCMV infections in
transplant recipients this has to be kept in mind in patients with high viral loads during therapy (NCT01611974).
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Background
All compounds approved for systemic treatment of hu-
man cytomegalovirus (HCMV) infections target the viral
DNA polymerase [1-3]. Furthermore, all of these com-
pounds are limited by dose related toxicities and the
emergence of resistant virus mutants. The experimental
drug maribavir (MBV) primarily inhibits the viral UL97
kinase [3-5]. MBV is orally bioavailable and was shown
to have anti-HCMV activity in early clinical trials [6-8].
However, this activity could not be confirmed in a phase
III prophylaxis trial involving transplant recipients who
obtained 100 mg twice per day [9]. Recently, MBV was
used in a salvage treatment study using a higher dosage
of 400 mg twice per day in 6 cases, who had failed to re-
spond to other therapies and/or had known ganciclovir-
resistant HCMV [10]. In one of these patients, a heart
transplant recipient, genotypic MBV resistance has been
observed after 10 weeks of MBV treatment [10,11]. To
our knowledge with the exception of this solid organ re-
cipient no other cases of genotypic MBV resistance in
treated patients have been published so far. Here, we de-
scribe the fast emergence of individual cytomegalovirus
variants with different maribavir resistance associated
mutations in a bone marrow transplant recipient treated
with MBV 400 mg p.o. twice per day.
Methods
Maribavir was supplied by ViroPharma and administered
at a dose of 400 mg p.o. twice per day.
Genotypic resistance testing was performed by poly-
merase chain reaction (PCR) amplification of a 870 bp
HCMV UL97 region [12] and a 2.1 kb fragment of the
viral polymerase (UL54, codons 300–1000) directly from
EDTA blood and urine samples. DNA sequencing of
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UL97 was performed allowing detection of all described
mutations conferring ganciclovir resistance and most of
the mutations described after in vitro selected maribavir
resistance. DNA sequencing of UL54 was performed
allowing detection of all described mutations con-
ferring resistance against ganciclovir, cidofovir, and
foscarnet. To determine whether multiple mutations
detected in patient’s specimens occurred within the
same or different viral genomes, UL97 fragments were
amplified from the extracted DNA, ligated into the
cloning vector pJET1.2/blunt (Fermentas, Lituania)
and transfected into E. coli DH5α. The UL97 regions
of the resulting clones were sequenced as described
above.
Case presentation
The bone marrow transplant recipient was a 13-year-old
HCMV seropositive girl. The diagnosis of refractory
cytopenia in July 2010 without genetic and molecular
abnormalities was followed by bone marrow transplant-
ation (BMT).
Before transplantation in March 2011 supportive treat-
ment with transfusions and antibiotics was given. The
non-myeloablative regimen with fludarabine (4x40 mg/
m2), thiotepa (3x5 mg/kg KG) and anti-thymocyte
globulin (3x20 mg/kg KG) was followed by transfusion
of the marrow transplant from an unrelated 10/10 com-
patible HCMV seronegative (D-) donor. Neutrophil en-
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Figure 1 Time course of antiviral treatments and events. The viral loads of adenovirus (dashed) and HCMV are depicted as DNA copies per
ml EDTA blood. The durations of treatments with ganciclovir, foscarnet and cidofovir are shown as black boxes and with maribavir as grey boxes,
respectively. Ribavirin and leflunomide are presented as blank boxes. The boost with selected CD34+ cells is depicted as black star. The
administration of adenovirus-specific T-cells is illustrated by a white star. Tx, transplantation; UL97, HCMV UL97 kinase; wt, wild type; pol, HCMV
polymerase (UL54). Mutations detected by direct genotyping from the specimens are shown in the single letter code (L592S, lysine at amino acid
595 to serine). The mutation H411N (brackets) was detected by cloning but not by direct genotyping. ADV, adenovirus; n.d., not detected.
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After detection of an active HCMV infection at week
six post transplantation, foscarnet was administered
because of lower hematotoxic side effects (see Figure 1).
However, after one week this therapy had to be dis-
continued because of ulcera in the genital and in the oral
mucosa. Due to the ongoing viral replication, at week 10,
a therapy with foscarnet (180 mg/kg KG) and ganciclovir
(10 mg/kg KG) was initiated for 3 weeks, resulting in a
considerable decrease of the viral load in the blood.
However, during this period the girl developed lung
infiltrates consistent with the diagnosis of viral induced
pneumonia. At this time, UL97 and UL54 genotyping
revealed wild-type sequences. The virus carried the UL97
polymorphism D605E as a genetic marker, which is not
associated with ganciclovir resistance [13].
Foscarnet therapy was again discontinued at week 13
due to adverse side effects. After onset of an acute graft-
versus-host-disease (GvHD), followed by an intensified
immunosuppressive therapy, at week 25 a stem cell
boost with selected CD34-positive peripheral blood stem
cells became necessary, because of a secondary graft
failure. During this period a substantial increase of the
HCMV viral load up to more than 106 genome equiva-
lents per ml (ge/ml) in EDTA blood occurred. UL97
genotyping revealed the emergence of HCMV variants
with mutations, M460V and L595S, conferring GCV
resistance. Additionally, due to an active adenovirus
(species A) infection in August 2011 cidofovir and riba-
virin were administered.
Since one cycle of cidofovir (5 mg/kg KG) did not
result in a significant reduction of the HCMV viral load,
a salvage therapy was induced which consisted of leflu-
nomide (80 mg p.o. initially for the first two days, followed
by 20 mg once per day) and maribavir (starting dose of
MBV was 400 mg p.o. twice per day). The duration of
treatment over five weeks resulted in an improvement and
the patient experienced a temporary decline of the
HCMV viral load to approximately 104 ge/ml. The virus
load remained at that level.
A transfusion of adenovirus-specific donor-derived T-
cells was performed in October (week 29). One week
after termination of the salvage therapy, UL97 genotyping
revealed that the M460V variant was no longer detectable.
However, the L595S mutation was still present. Since the
UL54 genotyping exhibited no resistance-associated muta-
tion, foscarnet therapy was again initiated at week 32. At
week 35 an increase in the virus load was observed associ-
ated with a relapse of pneumonitis. Therefore, a new ad-
justment of therapy with MBV (400 mg p.o. twice per day)
was initiated. Two weeks later genotyping revealed a com-
pilation of different UL97 and UL54 mutations. The UL54
sequences showed a mixture of T700A and A809V confer-
ring potential low resistance to GCV and resistance to fos-
carnet, respectively [14]. In addition to the already known
mutation L595S, a new mutation was detected in the
UL97 region, namely the mutation H411Y which has been
described to confer resistance to maribavir [15]. However,
the combination therapy with foscarnet and MBV was
continued due the low proportion of MBV resistant virus
in the patient and the lack of alternative compounds.
At week 40 foscarnet was withdrawn. After two further
weeks of MBV administration, UL97 genotyping exhibited
an increase of the virus population carrying the mutation
H411Y and further more, the emergence of a second
mutation T409M also conferring MBV resistance [15].
In order to solve the question whether the detected mix-
ture of mutations consisted of different single, double or
multiple HCMV mutants, UL97 amplicons were cloned
into E.coli and individual clones were further analyzed.
Sequencing revealed that all clones (n=33) carried the
UL97 marker polymorphism D605E. Most of the clones
carried wild type UL97 sequences (67%). However, certain
clones carried one of the mutations L592S, H411Y, or
T409M. As already reported by Strasfeld et al. [11] in a
solid organ recipient, none of the clones contained more
than one single resistance mutation which indicates that
the mutations were located on separate viral genomes.
Surprisingly, one clone exhibited the mutation H411N
also conferring MBV resistance which had not been
detected by the direct sequencing of UL97 from the
patient’s specimens. Regrettable, despite several attempts
no virus isolates could be obtained.
Fortunately, the patient recovered from the HCMV
and adenovirus infection. Until today she did not ex-
perience further serious virus associated events and can
attend school.
Discussion
In this study we present data that maribavir resistance
occurred relatively rapid in a bone marrow transplant
(BMT) recipient after less than 6 weeks of MBV treat-
ment. Previous MBV trials included mainly short dura-
tions of treatment of up to four weeks or prophylactic
use of up to 12 weeks in patients without active infec-
tion at the onset [6-9]. Therefore, in these studies drug
resistance was not detected.
Avery and coworkers presented data from six patients
(five solid organ transplant recipients and one hema-
topoietic stem cell transplant recipient) who had failed
to respond to other therapies and/or carried a known
ganciclovir-resistant HCMV [10]. The starting dose of
MBV was 400 mg p.o. twice per day and was increased
up to 800 mg twice per day in one patient. Patients were
treated for a median of 207 days (range, 15 to 376). Four
of the 6 patients had no detectable HCMV DNAemia
within 6 weeks after starting MBV therapy. One solid
organ recipient, who had an initial high viral load, devel-
oped a MBV resistance mutation.
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In our patient, MBV resistance was associated with an
initial high viral load that could not be cleared with
ganciclovir, cidofovir, foscarnet, lefunomide or maribavir.
The patient developed genotypic MBV resistance after a
second short period of therapy. This is the first docu-
mented case of genotypic resistance against this drug in
a bone marrow transplant recipient. Probably, the high
virus load permitted the faster selection of several, indi-
vidual UL97 mutants shortly after readministration of
MBV.
In vitro data show that UL97 mutations V353A, L397R,
T409M, and H411L/N/Y, are all located near the kinase
ATP binding domain, and confer moderate to high levels
of MBV resistance without GCV cross-resistance [3,5,15].
The mutations T409M, and H411Y found in our patient
after direct sequencing belong to the most common
mutations induced in vitro and confer a ∼9-fold to ∼200-
fold increase in IC50 values [5,15]. Surprisingly, several
independent mutated virus variants have been identified
in our patient. After analysis of cloned UL97 amplicons,
none of the clones contained more than one single mu-
tation. This indicates that several mutated virus variants
were selected separately during treatment which is in
agreement with data from Strasfeld et al. [11]. Further-
more, by detection of the H411N mutation after sequen-
cing separate E. coli clones we could show that individual
HCMV variants might be present in the patient being
beyond the detection limit of the routinely performed
direct genotyping from patient specimens.
Notably, in vitro results suggest that the GCV-resist-
ance mutations M460V/I confer MBV hypersensitivity
[5]. These findings might be supported by our results
in vivo. After the onset of the maribavir therapy, the
M460V mutation disappeared but not the L594S.
Although UL97 deficient strains are highly impaired in
their replication capacity, it remains questionable whether
MBV should be administered as salvage therapy to im-
munosuppressed patients with a high viral load at the
beginning and during therapy at all.
In conclusion, therapy adjustment in immunosup-
pressed patient with high virus loads over longer periods
should only be done after HCMV genotyping. This holds
true particularly for the changing from a usually effective
antiviral drug with fewer side effects (e.g. GCV) to anti-
viral drugs with less efficiency or higher toxicity (e.g.
cidofovir or foscarnet, respectively) without any evidence
of viral drug (genotypic or phenotypic) resistance. Further-
more, due to short time drug changes different HCMV
mutants might be selected from the virus population.
Conclusion
Our case suggests that a high virus load permitted fast
selection of several, individual UL97 mutants and may
contribute to a faster occurrence of overall (multi-) drug
resistance. Since a phase II study with MBV is intended
for the treatment of resistant HCMV or HCMV infections
after treatment failure in transplant recipients this has to
be kept in mind in patients with a high viral load at the be-
ginning or during antiviral therapy (NCT01611974) [16].
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